QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module V — Risk Management Systems

Test your understanding of the concepts covered by GVP Module V: Risk Management Systems.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement correctly distinguishes routine from additional risk-minimisation measures?

Routine measures are voluntary, whereas additional measures are always mandatory. Routine measures are part of the normal regulatory and healthcare framework; additional measures are used when routine measures are insufficient for an important risk. Routine measures address identified risks, whereas additional measures address only missing information. Additional measures are used instead of product information in every case.

Question 2 of 10 Which statement best describes the QPPV's role in risk-management oversight?

The QPPV must personally perform every RMP assessment and every risk-minimisation activity. The QPPV should have appropriate oversight of material PV aspects, understand significant concerns and escalate material weaknesses where necessary. The QPPV's role ends once the RMP has been submitted to the authority. The QPPV is responsible only for vendor invoices associated with RMP activities.

Question 3 of 10 Which scenario is most consistent with an important identified risk?

A clinically relevant event with sufficient evidence supporting an association with the medicine A theoretical concern based only on a class effect with no product-relevant supporting evidence A population for which exposure data are insufficient to assess safe use A single unassessed spontaneous report with no supporting information

Question 4 of 10 An educational letter is distributed to healthcare professionals to improve understanding of a serious risk. Which evaluation approach is strongest?

Count only how many letters were printed. Confirm distribution and, where appropriate, assess reach, understanding and whether the intended risk-reduction objective was achieved. Assume effectiveness because the letter was approved by the regulator. Measure only the number of adverse-event reports received after distribution.

Question 5 of 10 Which operational control is most important when an RMP includes an additional risk-minimisation measure?

Ensuring that the measure is described in the RMP, regardless of operational ownership Assigning responsibility for implementation, defining relevant interfaces and maintaining evidence of delivery and monitoring Delegating all accountability to the healthcare professionals who receive the measure Updating only the RMP while leaving product-information and distribution processes unchanged

Question 6 of 10 Which statement best reflects the dynamic nature of an RMP?

Once approved, an RMP should remain unchanged unless the product is withdrawn. An RMP should be reassessed when new evidence changes the classification, characterisation, evidence needs or adequacy of measures. An RMP is dynamic only when a new adverse reaction is confirmed. RMP updates are driven exclusively by periodic administrative schedules.

Question 7 of 10 What is the primary purpose of a safety specification?

To list every adverse event observed during development in descending frequency To provide a structured assessment of important safety concerns, uncertainties and relevant information for risk-management planning To document only risks already included in the Summary of Product Characteristics To replace signal management and periodic safety evaluation

Question 8 of 10 Why does risk management need to continue after marketing authorisation?

Post-authorisation use eliminates the need to consider clinical trial evidence. Real-world exposure may involve broader populations, longer use and clinical circumstances not adequately represented in trials. The RMP is legally required to change at every reporting cycle regardless of new evidence. Routine pharmacovigilance cannot be conducted before authorisation.

Question 9 of 10 A major change to a safety concern has been approved internally. Which change-control approach is most appropriate?

Update the RMP only, because other systems are outside Module V. Assess the potential impact on the RMP, safety classifications, signals, aggregate reporting, product information, communications, vendors, monitoring and training. Wait for the next routine RMP revision before considering operational consequences. Change the product information immediately without regulatory assessment.

Question 10 of 10 What best distinguishes an important potential risk from an important identified risk?

A potential risk is always less clinically serious than an identified risk. A potential risk has a basis for suspicion, but evidence is insufficient to establish the association as an identified risk. A potential risk is limited to events found in non-clinical studies. A potential risk is any adverse event that has not yet been included in the product information.

Knowledge Assessment: GVP Module V — Risk Management Systems

Cookie Settings